The Stelo is available to anyone who wants to monitor their blood glucose, no prescription needed. But as an active adult without diabetes, are these extra data points worth $99 per month?

Your cozy Pokémon adventure in Pokopia begins right here in the Withered Wasteland! In this walkthrough, we’ll show you exactly how to wake up your Ditto-humanoid avatar, meet Professor Tangrowth, and ...

SAN DIEGO - DexCom, Inc. (NASDAQ:DXCM) announced the appointment of Rick Osterloh to its Board of Directors, effective today, according to a press release statement. Osterloh serves as Senior Vice ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 47th Annual Raymond James Institutional Investors Conference on ...

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 47th Annual Raymond James Institutional Investors Conference on Monday, March 2, 2026. The live ...

Dexcom has achieved revenues of $4.66bn in 2025 and beat analysts’ consensus for Q4 performance amid a strong demand for its continuous glucose monitoring (CGM) systems. Yet its 2026 outlook was lower ...

Jacob Steven Leach, DexCom, Inc.'s President and CEO who will summarize our recent highlights and ongoing strategic initiatives. Followed by a financial review and outlook from Jereme M. Sylvain, our ...

Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in a new awareness campaign. The project kicked off Friday, World Diabetes Day ...

New RAMQ coverage means eligible Québec residents with type 2 diabetes on intensive insulin therapy can now access Dexcom Continuous Glucose Monitoring (CGM) to simplify diabetes management. Dexcom, ...

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...

Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...